New, long-acting form of nifedipine: efficacy and safety in patients with mild to moderate arterial hypertension
Abstract
The aim of the study was to compare efficacy and safety of a new, prolonged-action nifedipine form - nifecard-XL, and standard nifedipine tablets, in arterial hypertension (AH). One hundred forty-seven individuals with mild to moderate AH (61 males, 86 females), aged 21-81, were included. In a randomized, cross-over study, patients were consecutively administered nifecard-XL (30 mg once a day), or corinfar (10 mg 3 times a day), for one month each. In non-responders, the dose was doubled after 2 weeks. Before 1st and 2nd course, there were control one-week periods, with all antihypertensives withdrawn. Efficacy was assessed during blood pressure (BP) office measurements and 24-hour BP monitoring. Total number of persons who completed the trial was 127. Nifecard-XL (30 mg per day) was effective in 108 articipants, and in another 29 daily dose of 60 mg was needed. Corinfar (30 mg a day) was effective in 93 patients, and another 41 individuals had to be administered 60 mg. Mean daily dose for nifecard-XL was 36.4+12.3 mg, for corinfar - 39.2+13.9 mg. According to office BP levels, nifecard-XL significantly better lowered systolic BP than corinfar. Both agents were equal in reducing diastolic BP. During 24-hour BP monitoring, nifecard-XL and corinfar significantly decreased systolic, diastolic, and mean BP, temporal indexes of systolic and diastolic BP, without any substantial differences between both agents. Adverse events were typical for this class of antihypertensives, with 33 events registered in corinfar group, and 16 - in nifecard-XL group.
About the Authors
E. V. Alimova
Государственный научно2исследовательский центр профилактической медицины МЗ и СР России
Russian Federation
Russian Federation
S. Yu. Martsevich
Государственный научно2исследовательский центр профилактической медицины МЗ и СР России
Russian Federation
Russian Federation
V. M. Gorbunov
Государственный научно2исследовательский центр профилактической медицины МЗ и СР России
Russian Federation
Russian Federation
A. D. Deev
Государственный научно2исследовательский центр профилактической медицины МЗ и СР России
Russian Federation
Russian Federation
V. N. Khirmanov
Санкт-Петербургская государственная медицинская академия им. И. И.Мечникова
Russian Federation
Russian Federation
L. A. Sokolova
Санкт-Петербургская государственная медицинская академия им. И. И.Мечникова
Russian Federation
Russian Federation
V. I. Podzolkov
Московская медицинская академия им. И.М.Сеченова
Russian Federation
Russian Federation
Yu. A. Karpov
Российский кардиологический научно-производственный комплекс МЗ и СР России
Russian Federation
Russian Federation
References
1. Brogden R.N., McTavish D.M. Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris//Drugs 1995-50-C.495-512.
2. Brown M.J. et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)//Lancet 2000-356-C.366-372.
3. DeQuattro V., Li D., Lu Z.H. et al. Improved early morning blood pressure control with nifedipine GITS versus enalapril (once a day) despite equivalency in reduction of proteinuria in elderly hypertensives//Can. J. Physiol. Pharmacol. 1994. 72:Suppl. 1:135.
4. Hansson L. "Why don't you do as I tell you?" Compliance and antihypertensive regimens//Internat J. Clin. Practice 2002-56-C.191-196.
5. Krakoff L.R., Bravo E.L., Tuck M.L. et al. Nifedipine gastrointestinal therapeutic system in the treatment of hypertension//Am. J. Hypertens. 1990; 3: 318S-325S.
6. Salvetti A., Virdis A., Taddei S. et al. Trough: peak ratio of nifedipine gastrointestinal therapeutic system and nifedipine retard in essential hypertensive patients: an Italian multicentre study//J. Hypertens. 1996; 14: С 661-667.
7. S.Mohiuddin, D.Hilleman. Substituting nifedipine-GITS for immediate release calcium-channel antagonists in patients with stable angina pectoris//Curr. Ther. Res. -1991.-50-C.546-552.
Review
For citations:
Alimova E.V., Martsevich S.Yu., Gorbunov V.M., Deev A.D., Khirmanov V.N., Sokolova L.A., Podzolkov V.I., Karpov Yu.A. New, long-acting form of nifedipine: efficacy and safety in patients with mild to moderate arterial hypertension. Russian Journal of Cardiology. 2004;(4):49-52. (In Russ.)
Views:
992
Email this article 